Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1982 2
1983 2
1984 4
1985 6
1986 3
1987 11
1988 9
1989 6
1990 5
1991 8
1992 2
1993 2
1994 5
1995 2
1996 3
1997 3
1998 6
1999 4
2000 6
2001 2
2002 1
2005 2
2007 4
2008 4
2009 2
2010 1
2011 3
2012 1
2013 3
2014 2
2015 4
2016 3
2018 1
2019 1
2020 2
2021 1
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group. Roos I, et al. JAMA Neurol. 2023 Aug 1;80(8):789-797. doi: 10.1001/jamaneurol.2023.1625. JAMA Neurol. 2023. PMID: 37307006 Free PMC article.
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group. Kalincik T, et al. JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184. JAMA Neurol. 2023. PMID: 37437240 Free PMC article.
[Late neurosyphilis: a current disease].
Chemouilli P, Amarenco P, Roullet E, Marteau R. Chemouilli P, et al. Among authors: roullet e. Rev Med Interne. 1989 Nov-Dec;10(6):503-8. doi: 10.1016/s0248-8663(89)80066-9. Rev Med Interne. 1989. PMID: 2488500 Review. French.
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
Li Y, Saul A, Taylor B, Ponsonby AL, Simpson-Yap S, Blizzard L, Broadley S, Lechner-Scott J; Ausimmune/AusLong Investigators Group; Karabudak R, Patti F, Eichau S, Onofrj M, Ozakbas S, Horakova D, Kubala Havrdova E, Grand'Maison F, Alroughani R, Gerlach O, Amato MP, Altintas A, Girard M, Duquette P, Blanco Y, Ramo-Tello C, Laureys G, Kalincik T, Khoury SJ, Shaygannejad V, Etemadifar M, Singhal B, Mrabet S, Foschi M, Habek M, John N, Hughes S, McCombe P, Ampapa R, van der Walt A, Butzkueven H, de Gans K, McGuigan C, Oreja-Guevara C, Sa MJ, Petersen T, Al-Harbi T, Sempere AP, Van Wijmeersch B, Grigoriadis N, Prevost J, Gray O, Castillo-Triviño T, Macdonell R, Lugaresi A, Sajedi SA; MSBase; van der Mei I. Li Y, et al. J Neurol. 2024 Jan;271(1):472-485. doi: 10.1007/s00415-023-11980-z. Epub 2023 Sep 28. J Neurol. 2024. PMID: 37768389 Free PMC article.
[Childhood multiple sclerosis].
Roullet E. Roullet E. Rev Neurol (Paris). 1998 Sep;154(8-9):619-22. Rev Neurol (Paris). 1998. PMID: 9809377 French.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. O'Connor P, et al. N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656. N Engl J Med. 2011. PMID: 21991951 Free article. Clinical Trial.
Leuko-araiosis in severe amyloid angiopathy.
Roullet E, Gray FF. Roullet E, et al. Arch Neurol. 1988 Feb;45(2):140. doi: 10.1001/archneur.1988.00520260026012. Arch Neurol. 1988. PMID: 3341927 No abstract available.
Risk of relapse phenotype recurrence in multiple sclerosis.
Kalincik T, Buzzard K, Jokubaitis V, Trojano M, Duquette P, Izquierdo G, Girard M, Lugaresi A, Grammond P, Grand'Maison F, Oreja-Guevara C, Boz C, Hupperts R, Petersen T, Giuliani G, Iuliano G, Lechner-Scott J, Barnett M, Bergamaschi R, Van Pesch V, Amato MP, van Munster E, Fernandez-Bolanos R, Verheul F, Fiol M, Cristiano E, Slee M, Rio ME, Spitaleri D, Alroughani R, Gray O, Saladino ML, Flechter S, Herbert J, Cabrera-Gomez JA, Vella N, Paine M, Shaw C, Moore F, Vucic S, Savino A, Singhal B, Petkovska-Boskova T, Parratt J, Sirbu CA, Rozsa C, Liew D, Butzkueven H; MSBase Study Group. Kalincik T, et al. Mult Scler. 2014 Oct;20(11):1511-22. doi: 10.1177/1352458514528762. Epub 2014 Apr 28. Mult Scler. 2014. PMID: 24777276
125 results